US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by Oculis SA

News headline image
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis to Participate and Present at Upcoming EuDES Meeting
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis to Participate at Upcoming Investor Conferences
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
From Oculis SA
Via GlobeNewswire
Tickers OCS
News headline image
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
From Oculis SA
Via GlobeNewswire
Tickers OCS